BCRX BIOCRYST PHARMACEUTICALS INC

Nasdaq biocryst.com


$ 6.99 $ 0.13 (1.82 %)    

Wednesday, 05-Nov-2025 10:10:42 EST
QQQ $ 621.53 $ 3.08 (0.5 %)
DIA $ 472.45 $ 1.58 (0.33 %)
SPY $ 677.37 $ 2.37 (0.35 %)
TLT $ 89.19 $ -0.32 (-0.35 %)
GLD $ 365.45 $ -1.00 (-0.27 %)
$ 6.76
$ 6.87
$ 6.98 x 200
$ 6.99 x 390
$ 6.87 - $ 7.18
$ 6.00 - $ 11.31
8,818,662
na
1.42B
$ 0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-05-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-13-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-14-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-12-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-08-2017 03-31-2017 10-Q
36 02-27-2017 12-31-2016 10-K
37 11-08-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-26-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citizens-maintains-market-outperform-on-biocryst-pharma-lowers-price-target-to-25

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and lowers the price tar...

 barclays-maintains-equal-weight-on-biocryst-pharma-lowers-price-target-to-9

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and lowers the price target from $11 ...

 needham-maintains-buy-on-biocryst-pharma-lowers-price-target-to-18

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $20 to $18.

 top-stocks-with-earnings-this-week-joby-ionq-amd-and-more

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Fr...

 biocryst-pharma-raises-fy2025-sales-guidance-from-580000m-600000m-to-590000m-600000m-vs-625558m-est

BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to $590.000 million-$600.000 m...

 biocryst-pharma-q3-adj-eps-016-beats-004-estimate-sales-159395m-miss-162974m-estimate

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04...

 biocryst-pharmaceuticals-to-present-four-abstracts-from-second-interim-analysis-of-apex-p-trial-at-annual-scientific-meeting-of-the-american-college-of-allergy-asthma--immunology-in-orlando-florida

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scient...

 td-cowen-reinstates-buy-on-biocryst-pharma-announces-30-price-target

TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.

 cantor-fitzgerald-maintains-overweight-on-biocryst-pharma-raises-price-target-to-26

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price ta...

 jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-27

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

 needham-maintains-buy-on-biocryst-pharma-raises-price-target-to-20

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $17 to $20.

 biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

 biocryst-pharmaceuticals-and-biocryst-ireland-entered-into-a-trademark-license-agreement

-SEC Filing

 ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

 needham-maintains-buy-on-biocryst-pharma-maintains-17-price-target

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $17 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION